{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:17:11Z","timestamp":1794712631379,"version":"4.9.1"},"reference-count":60,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>TP53 mutations are found in 10% to 15% of myeloid neoplasms and are associated with a dismal prognosis. Although hypomethylating agents (HMAs), such as decitabine, are active in TP53-mutated myeloid neoplasms (TP53-MN), mutation clearance is rarely complete and nearly all patients relapse. Molecular determinants of response to HMAs in TP53-MN are poorly understood. Here, we show that decitabine induces replicative stress with decreased replication fork progression, induction of single-strand DNA breaks, and activation of the ataxia telangiectasia mutated\u2013Rad3-related (ATR) pathway. Resolution of decitabine-induced replication stress is impaired in TP53-mutated acute myeloid leukemia (AML) cells, representing a potential therapeutic vulnerability. Indeed, the combination of decitabine and ATR inhibition (ATRi) induces synthetic lethality that is selective for TP53-AML and due, in part, to induction of mitotic catastrophe. Interestingly, this synergistic lethality was not observed with azacitidine or treatment with GSK3685032, a potent DNA methyltransferase 1 inhibitor, both of which produce a comparable level of global hypomethylation to decitabine. Treatment with decitabine and an ATR inhibitor reduces leukemia burden and prolongs survival in in vivo mouse models of TP53-mutated AML. Collectively, these findings show that TP53 loss generates a selective vulnerability to decitabine-induced replication stress, with the combination of ATRi and decitabine showing promise as a new therapeutic approach for TP53-MN.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018369","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T20:13:21Z","timestamp":1769717601000},"page":"2506-2520","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Synthetic lethality of decitabine plus ATR inhibition for\n                    <i>TP53<\/i>\n                    -mutated AML"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1466-4604","authenticated-orcid":false,"given":"Jeremy T.","family":"Baeten","sequence":"first","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9138-6169","authenticated-orcid":false,"given":"Sumedha","family":"Agashe","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2172-461X","authenticated-orcid":false,"given":"Imene","family":"Tabet","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack T.","family":"Wooldridge","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Carter","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie N.","family":"Butler","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4266-6700","authenticated-orcid":false,"given":"Christopher A.","family":"Miller","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Helton","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0852-6181","authenticated-orcid":false,"given":"Annabel","family":"Quinet","sequence":"additional","affiliation":[{"name":"2Stabilit\u00e9 G\u00e9n\u00e9tique Cellules Souches et Radiations Unit, Institut de Biologie Fran\u00e7ois Jacob, Commissariat \u00e0 l\u2019Energie Atomique et aux Energies Alternatives, Universit\u00e9 Paris-Saclay, Fontenay-aux-Roses, France"},{"name":"3Stabilit\u00e9 G\u00e9n\u00e9tique Cellules Souches et Radiations Unit, Universit\u00e9 Paris Cit\u00e9, INSERM, Fontenay-aux-Roses, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7096-8602","authenticated-orcid":false,"given":"Kimberly B.","family":"Johansson","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO"},{"name":"4Medical Scientist Training Program, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2860-030X","authenticated-orcid":false,"given":"Yichan","family":"Yang","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7809-0996","authenticated-orcid":false,"given":"Geoffrey L.","family":"Uy","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0568-5067","authenticated-orcid":false,"given":"Alessandro","family":"Vindigni","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3170-7581","authenticated-orcid":false,"given":"Daniel C.","family":"Link","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"issue":"22","key":"2026041408024375000_bib1","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1002\/cncr.30203","article-title":"TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes","volume":"122","author":"Kadia","year":"2016","journal-title":"Cancer"},{"issue":"5","key":"2026041408024375000_bib2","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","article-title":"Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia","volume":"128","author":"Metzeler","year":"2016","journal-title":"Blood"},{"issue":"23","key":"2026041408024375000_bib3","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"2026041408024375000_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/leu.2016.163","article-title":"Subtype-specific patterns of molecular mutations in acute myeloid leukemia","volume":"31","author":"Rose","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"2026041408024375000_bib5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/leu.2016.263","article-title":"The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases","volume":"31","author":"Stengel","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"2026041408024375000_bib6","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"R\u00fccker","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2026041408024375000_bib7","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/bjh.13912","article-title":"TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation","volume":"172","author":"Middeke","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"2026041408024375000_bib8","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/leu.2014.335","article-title":"Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial","volume":"29","author":"Schetelig","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"2026041408024375000_bib9","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2026041408024375000_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13045-023-01417-5","article-title":"Treatment outcomes for newly diagnosed, treatment-na\u00efve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis","volume":"16","author":"Daver","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"21","key":"2026041408024375000_bib64","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"2026041408024375000_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrg.2017.80","article-title":"The DNA methyltransferase family: a versatile toolkit for epigenetic regulation","volume":"19","author":"Lyko","year":"2018","journal-title":"Nat Rev Genet"},{"issue":"22","key":"2026041408024375000_bib12","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.1073\/pnas.81.22.6993","article-title":"Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine","volume":"81","author":"Santi","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"46","key":"2026041408024375000_bib13","doi-asserted-by":"crossref","first-page":"11018","DOI":"10.1021\/bi00110a002","article-title":"Direct identification of the active-site nucleophile in a DNA (cytosine-5)-methyltransferase","volume":"30","author":"Chen","year":"1991","journal-title":"Biochemistry"},{"issue":"8","key":"2026041408024375000_bib14","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.4161\/epi.6.8.16064","article-title":"The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2'deoxycytidine (decitabine) are differentially regulated by cell cycle progression","volume":"6","author":"Al-Salihi","year":"2011","journal-title":"Epigenetics"},{"issue":"2","key":"2026041408024375000_bib15","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1128\/MCB.01799-07","article-title":"DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B","volume":"28","author":"Palii","year":"2008","journal-title":"Mol Cell Biol"},{"issue":"25","key":"2026041408024375000_bib16","doi-asserted-by":"crossref","first-page":"8905","DOI":"10.1073\/pnas.0501034102","article-title":"Recruitment of DNA methyltransferase I to DNA repair sites","volume":"102","author":"Mortusewicz","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2026041408024375000_bib17","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0165-6147(02)02033-3","article-title":"J DNA\u2013protein adducts: hijacking one repair process to examine another","volume":"23","author":"Gillam Elizabeth","year":"2002","journal-title":"Trends in Pharmacol Sci"},{"issue":"9","key":"2026041408024375000_bib59","doi-asserted-by":"crossref","first-page":"113098","DOI":"10.1016\/j.celrep.2023.113098","article-title":"Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment","volume":"42","author":"Yabushita","year":"2023","journal-title":"Cell Rep"},{"issue":"21","key":"2026041408024375000_bib18","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","article-title":"Molecular pathways: targeting ATR in cancer therapy","volume":"21","author":"Larry M. Karnitz","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"18","key":"2026041408024375000_bib19","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1038\/sj.onc.1208474","article-title":"Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities","volume":"24","author":"He","year":"2005","journal-title":"Oncogene"},{"issue":"7","key":"2026041408024375000_bib20","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.celrep.2016.10.036","article-title":"p53 activity results in DNA replication fork processivity","volume":"17","author":"Klusmann","year":"2016","journal-title":"Cell Rep"},{"key":"2026041408024375000_bib21","doi-asserted-by":"crossref","first-page":"e31723","DOI":"10.7554\/eLife.31723","article-title":"p53 orchestrates DNA replication restart homeostasis by suppressing mutagenic RAD52 and POL\u03b8 pathways","volume":"7","author":"Roy","year":"2018","journal-title":"eLife"},{"issue":"22","key":"2026041408024375000_bib22","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1038\/onc.2010.624","article-title":"ATR mediates cisplatin resistance in a p53 genotype-specific manner","volume":"30","author":"Sangster-Guity","year":"2011","journal-title":"Oncogene"},{"issue":"8","key":"2026041408024375000_bib23","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/ng.420","article-title":"A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging","volume":"41","author":"Murga","year":"2009","journal-title":"Nat Genet"},{"issue":"10","key":"2026041408024375000_bib24","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/ng.441","article-title":"Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53","volume":"41","author":"Ruzankina","year":"2009","journal-title":"Nat Genet"},{"issue":"5","key":"2026041408024375000_bib25","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2015-05-644872","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2026041408024375000_bib26","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2012-09-459313","article-title":"Genomic impact of transient low-dose decitabine treatment on primary AML cells","volume":"121","author":"Klco","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2026041408024375000_bib27","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1038\/s41375-023-02057-x","article-title":"Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemia","volume":"37","author":"Johansson","year":"2023","journal-title":"Leukemia"},{"key":"2026041408024375000_bib30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/bs.mie.2017.03.019","article-title":"DNA fiber analysis: mind the gap","volume":"591","author":"Quinet","year":"2017","journal-title":"Methods Enzymol"},{"issue":"49","key":"2026041408024375000_bib31","doi-asserted-by":"crossref","first-page":"eabq0648","DOI":"10.1126\/sciadv.abq0648","article-title":"NEDDylated Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors","volume":"8","author":"Alice Meroni","year":"2022","journal-title":"Sci Adv"},{"issue":"8","key":"2026041408024375000_bib33","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1182\/blood.2021012687","article-title":"S100A9 upregulated by IFNGR signaling blockade functions as a novel GVHD suppressor without compromising GVL in mice","volume":"141","author":"Kim","year":"2023","journal-title":"Blood"},{"issue":"W1","key":"2026041408024375000_bib34","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"2026041408024375000_bib35","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for drug synergy in complex dose-response landscapes using an interaction potency model","volume":"13","author":"Yadav","year":"2017","journal-title":"Comput Struct Biotechnol J"},{"issue":"3","key":"2026041408024375000_bib36","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/ng1982","article-title":"Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells","volume":"39","author":"Chen","year":"2007","journal-title":"Nat Genet"},{"issue":"20","key":"2026041408024375000_bib37","doi-asserted-by":"crossref","first-page":"7575","DOI":"10.1128\/MCB.01887-05","article-title":"DNA methyltransferase 1 knockdown activates a replication stress checkpoint","volume":"26","author":"Unterberger","year":"2006","journal-title":"Mol Cell Biol"},{"issue":"18","key":"2026041408024375000_bib63","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood.2025029691","article-title":"A clinical guide to TP53 mutations in myeloid neoplasms","volume":"146","author":"Urrutia","year":"2025","journal-title":"Blood"},{"issue":"4","key":"2026041408024375000_bib39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.biopha.2013.01.004","article-title":"Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2\/M phase through p53-independent pathway in human cancer cells","volume":"67","author":"Shin","year":"2013","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"2026041408024375000_bib40","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1091\/mbc.e05-07-0594","article-title":"Chk1 and p21 cooperate to prevent apoptosis during DNA replication fork stress","volume":"17","author":"Rodriguez","year":"2006","journal-title":"Mol Biol Cell"},{"issue":"5","key":"2026041408024375000_bib41","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00280-007-0531-7","article-title":"Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)","volume":"61","author":"Cashen","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"issue":"19","key":"2026041408024375000_bib42","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/1078-0432.CCR-21-1032","article-title":"Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: a phase I study","volume":"27","author":"Yap","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2026041408024375000_bib43","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/s43018-021-00249-x","article-title":"Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia","volume":"2","author":"Pappalardi","year":"2021","journal-title":"Nat Cancer"},{"key":"2026041408024375000_bib44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/bs.mie.2020.04.033","article-title":"Bioluminescence imaging in mice with synthetic luciferin analogues","volume":"640","author":"Ji","year":"2020","journal-title":"Methods Enzymol"},{"issue":"5","key":"2026041408024375000_bib45","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s41418-022-00999-w","article-title":"p53 at the crossroad of DNA replication and ribosome biogenesis stress pathways","volume":"29","author":"Lindstr\u00f6m","year":"2022","journal-title":"Cell Death Differ"},{"issue":"1","key":"2026041408024375000_bib46","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.celrep.2016.03.011","article-title":"p53 maintains genomic stability by preventing interference between transcription and replication","volume":"15","author":"Yeo","year":"2016","journal-title":"Cell Rep"},{"issue":"5","key":"2026041408024375000_bib47","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","article-title":"Cell cycle regulation: p53-p21-RB signaling","volume":"29","author":"Engeland","year":"2022","journal-title":"Cell Death Differ"},{"key":"2026041408024375000_bib48","doi-asserted-by":"crossref","first-page":"e18020","DOI":"10.7554\/eLife.18020","article-title":"Cyclin kinase-independent role of p21CDKN1A in the promotion of nascent DNA elongation in unstressed cells","volume":"5","author":"Sabrina F Mansilla","year":"2016","journal-title":"eLife"},{"issue":"11","key":"2026041408024375000_bib49","first-page":"2760","article-title":"Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia","volume":"30","author":"Li","year":"1970","journal-title":"Cancer Res"},{"issue":"suppl 1","key":"2026041408024375000_bib50","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1182\/blood-2024-208735","article-title":"Azacitidine versus decitabine for the treatment of myelodysplastic syndrome: a propensity score-matched retrospective cohort study using Trinetx","volume":"144","author":"Shanawar Waris","year":"2024","journal-title":"Blood"},{"key":"2026041408024375000_bib51","doi-asserted-by":"crossref","first-page":"107040","DOI":"10.1016\/j.leukres.2023.107040","article-title":"Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy","volume":"127","author":"Maurillo","year":"2023","journal-title":"Leuk Res"},{"issue":"3","key":"2026041408024375000_bib52","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood.2022015832","article-title":"Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy","volume":"140","author":"Amer M. Zeidan","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2026041408024375000_bib53","doi-asserted-by":"crossref","first-page":"EVIDoa2200034","DOI":"10.1056\/EVIDoa2200034","article-title":"Low-dose decitabine versus low-dose azacitidine in lower-risk MDS","volume":"1","author":"Sasaki","year":"2022","journal-title":"NEJM Evid"},{"issue":"1","key":"2026041408024375000_bib54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41598-019-56642-1","article-title":"Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study","volume":"10","author":"Lee","year":"2020","journal-title":"Sci Rep"},{"issue":"6","key":"2026041408024375000_bib55","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1016\/j.clml.2021.01.024","article-title":"Comparison of azacitidine and decitabine in myelodysplastic syndromes and acute myeloid leukemia: a network meta-analysis","volume":"21","author":"Liu","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2026041408024375000_bib56","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13148-022-01329-0","article-title":"Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line","volume":"14","author":"Aumer","year":"2022","journal-title":"Clin Epigenet"},{"issue":"1","key":"2026041408024375000_bib57","doi-asserted-by":"crossref","first-page":"6874","DOI":"10.1038\/s41598-023-33932-3","article-title":"The genome-wide mutational consequences of DNA hypomethylation","volume":"13","author":"Besselink","year":"2023","journal-title":"Sci Rep"},{"issue":"6","key":"2026041408024375000_bib58","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1093\/nar\/gkae031","article-title":"DNA hypomethylation activates Cdk4\/6 and Atr to induce DNA replication and cell cycle arrest to constrain liver outgrowth in zebrafish","volume":"52","author":"Madakashira","year":"2024","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"2026041408024375000_bib60","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1038\/s44318-024-00108-2","article-title":"Decitabine cytotoxicity is promoted by dCMP deaminase DCTD and mitigated by SUMO-dependent E3 ligase TOPORS","volume":"43","author":"Carnie","year":"2024","journal-title":"EMBO J"},{"issue":"1","key":"2026041408024375000_bib61","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/s41467-024-50498-4","article-title":"Inhibition of TOPORS ubiquitin ligase augments the efficacy of DNA hypomethylating agents through DNMT1 stabilization","volume":"15","author":"Kaito","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"2026041408024375000_bib62","doi-asserted-by":"crossref","first-page":"7360","DOI":"10.1038\/s41467-024-51646-6","article-title":"TOPORS E3 ligase mediates resistance to hypomethylating agent cytotoxicity in acute myeloid leukemia cells","volume":"15","author":"Truong","year":"2024","journal-title":"Nat Commun"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/7\/2506\/2512629\/blooda_adv-2025-018369-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/7\/2506\/2512629\/blooda_adv-2025-018369-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T12:02:55Z","timestamp":1776168175000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/7\/2506\/566328\/Synthetic-lethality-of-decitabine-plus-ATR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,4,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018369","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,14]]},"published":{"date-parts":[[2026,4,6]]}}}